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Abstract 
At least five mtDNA point mutations appear sufficient in themselves to cause Leber's hereditary optic neuropathy (LHON), while 
several other base substitutions act synergistically by increasing the risk for optic atrophy. The three most common mutations associated 
with LHON are ND4/11778, ND 1/3460 and ND6/14484 covering 50, 30 and 10% of the families, respectively, mtDNA heteroplasmy 
is seen most often in sporadic cases reflecting a recent mutational event. The etiology of LHON is still enigmatic. In addition to mtDNA 
mutations, nuclear gene interaction and environmental f ctors may contribute to the expression of optic atrophy. 
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1. Introduction 
Leber's hereditary optic neuroretinopathy (LHON) is 
characterized by acute or subacute, usually permanent 
bilateral loss of central vision. About 80% of affected 
individuals are male [1] and LHON can be considered as 
the most common cause of blindness in young and other- 
wise healthy men. LHON is maternally inherited and the 
mitochondrial transmission was confirmed when the 
mtDNA mutation at ND4/11778 was observed to be 
associated with the disease [2]. 
2. mtDNA mutations associated with LHON 
LHON is a heterogeneous disease. Several mtDNA 
point mutations have been proposed to be associated with 
LHON, all in the subunits of the electron-transport chain. 
Some of these mutations seem to be sufficient in them- 
selves to cause the disease. These primary mutations are 
not found in control individuals, and they alter evolutionar- 
ily considerably conserved amino acids. Furthermore, no 
case has been reported in which an individual harbours 
more than one primary mutation. Other mutations appear 
to have a synergistic deleterious effect when present simul- 
taneously with other mtDNA mutations. These secondary 
mutations are also found in control individuals, though at a 
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much lower frequency, and they alter less conserved amino 
acids. 
2. I. Primary mutations 
Altogether, five nucleotide changes fulfil the criteria for 
a primary mutation. Each of them is a mutation of a 
protein coding gene, three located in the subunits of com- 
plex I and two in the cytochrome c oxidase subunit III 
(complex IV). The most prevalent mutation, covering over 
50% of the cases, is the ND4/11778 [2-4]. This mutation 
is a G-to-A transition which converts a conserved arginine 
to a histidine. The ND4/11778 mutation has been associ- 
ated with poor visual outcome and prognosis [5,6] although 
spontaneous recoveries have also been reported [7,8]. 
The second primary mutation detected in LHON fami- 
lies is a G-to-A transition at the nt 3460 in the NDl-gene 
which changes a highly conserved alanine to a threonine 
[9,10]. The mutation is found worldwide, its frequency 
being about 15% of LHON families. The patients with the 
ND1/3460 mutation have a higher incidence of visual 
recovery compared to the patients with the ND4/11778 
mutation [11 ]. 
A T-to-C transition at nucleotide 14484 in the ND6-gene 
was found to be tightly linked to LHON phenotype [12]. 
The mutation converts a methionine to a valine in one of 
the most conserved omains of the ND6-gene. However, 
the conservation of the mutant residue and the nature of 
the amino acid substitution are less noteworthy than those 
seen in other primary mutations. The ND6/14484 is de- 
tected predominantly in association with the ND5/13708 
mutation considered to act as a secondary LHON mutation 
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[12,13] but is also found alone. About 10% of LHON 
families harbour the ND6/14484 mutation. Visual progno- 
sis of patients with the ND6/14484 mutation is more 
favourable than with the other primary mutations [14]. 
Recently, two new candidate mutations were detected in 
8 independent LHON families [15]. Both of them are 
G-to-A transitions in the cytochrome c oxidase subunit III 
gene, one at the nt 9438, the other at nt 9804. They both 
change highly conserved amino acids, the 9438 mutation a
serine to a glycine and the 9804 an alanine to a threonine. 
The 9438 mutation was detected in five independent LHON 
families while the 9804 was found in three families. 
Neither mutation was detected in controls nor in combina- 
tion with other primary mutations. The COXIII/9483 and 
COX/9804 mutations clearly fulfil the criteria for a pri- 
mary mutation for LHON and thus seem to have a 
pathogenic role in the etiology of LHON. 
Several authors consider a G-to-A transition at the cyt 
b/15257 a primary mutation for LHON [16,17]. This 
mutation changes an evolutionarily conserved aspartate to 
an asparagine. Johns and Neufield [16] detected the muta- 
tion in eight independent LHON probands, who did not 
harbour the ND4/11778 or NDI /3460 mutations and in 
none of the controls, while Brown et al. found [17] the 
mutation in four LHON patients who lacked the 
ND4/11778 mutation, and in one out of 362 control 
individuals. In both surveys all but one cyt b/15257 
positive patients also harboured the ND5/13708 mutation. 
In the Finnish series the cyt b/15257 mutation was de- 
tected in two ND4/11778 families, both harbouring also 
the ND5/13708 mutation [18]. Similarly, Howell et al. 
[19] have identified two families who carry both the 
ND4/11778 and the cyt b/15257 mutations. The role of 
the cyt b/15257 in the etiology of LHON is enigmatic. It 
changes an evolutionarily conserved amino acid and is 
found almost invariably in LHON families. Knowing that 
the penetrance of LHON is not complete, the single control 
individual with the cyt b/15257 mutation may be a non- 
penetrating LHON. The cyt b/15257 mutation thus fulfils 
the criteria for a primary mutation for LHON. However, 
contrary to other primary mutations which do not occur 
simultaneously, the cyt b/15257 is occasionally detected 
also in combination with the ND4/11778 mutation. Fur- 
thermore, the cyt b/15257 mutation seems to have a 
closer association with the secondary mutations, in particu- 
lar with the ND5/13708, compared to the previously 
identified primary mutations. Evidently, the cyt b/15257 
mutation has an etiological role in LHON, but relative to 
other primary mutations it has some features characteristic 
to the secondary mutations. 
2.2. Secondary mutations 
Several mtDNA substitutions are generally found in 
association with other mutations and they seem to act 
synergistically by increasing the probability of blindness. 
A secondary role in the pathogenesis of LHON has been 
reported at least for the following mutations: ND1/4216 
[20], ND2/4917 [20], ND2/5244 [17], COXI/74A.4 [21], 
ND5/13708 [20,17], and cyt b /15812 [17]. In addition, 
the sequence analysis of complex I, IV and V revealed the 
mutations ND1/4025, ND5/12811, ND5/13637, and 
ND5/13967 in three Finnish LHON families who do not 
harbour any of the previously detected primary mutations 
[18]. None of the mutations were detected in control 
individuals. The role of these mutations in the etiology of 
LHON will be elucidated when the genes for the rest of 
the respiratory chain complex are analyzed. 
3. Heteroplasmy in LHON 
Almost all pathogenic mtDNA mutations are charac- 
terized by heteroplasmy, i.e., they coexist with the wild- 
type mtDNA. LHON is an example of a mitochondrial 
disorder which harbours the primary mutations 
ND4/11778 or ND 1/3460 usually in a homoplasmic state 
[2,9], even though persistent low-level heteroplasmy has 
been reported [22,23]. Indisputably heteroplasmic families 
are often sporadic, and they account for approx. 14% of 
cases [5]. These families most likely reflect a recent muta- 
tional event dating only to few generations backwards. For 
reasons still unknown, the amount of mutated mtDNA 
tends to increase in successive generations. The fate of 
heteroplasmy in LHON resembles that of non-pathogenic 
mutations, first existing in a transitory heteroplasmic state 
and subsequently eading to complete homoplasmy within 
a few generations. 
According to several surveys on the clinical character- 
istics of LHON, it has been suggested that heteroplasmic 
persons are more likely to remain asymptomatic than those 
who are homoplasmic mutants [5,24,25]. However, a con- 
siderable proportion of offspring who are apparently ho- 
moplasmic for the mutated mtDNA remains asymptomatic. 
So far, there have been no studies on the target issues of 
LHON (optic nerve, retinal ganglion cells and vasculature) 
to firmly establish the threshold level for phenotypic ex- 
pression. As yet unknown nuclear gene interaction and 
environmental factors have been suggested to be of impor- 
tance for the development of LHON. 
Because it is likely that the proportion of the mutant 
mtDNA correlates with the penetrance and expressivity of 
LHON, an accurate quantification of heteroplasmy in 
LHON families is important to establish the level of 
mutant mtDNA high enough to put an individual at risk of 
expressing the disease. Solid-phase minisequencing is a 
method of choice for detection and quantification of het- 
eroplasmy in MERRF, MELAS [26,27] and LHON [28]. 
The method is based on primer-guided nucleotide incorpo- 
ration by DNA polymerase and it enables heteroplasmy of
1-2% to be easily detected. 
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4. Biochemistry of LHON 
Several ines of evidence indicate a pathogenic role of 
the most prevalent LHON mutations. However, little is 
still known about he energy metabolism in LHON. Majan- 
der et al. [29] have studied complex I electron transfer 
activity in mitochondria nd inner mitochondrial mem- 
branes derived from lymphoblastoid cell lines of patients 
with the ND4/11778 and the ND1/3460 mutation. The 
ND4 mutation had no effect on electron transfer activity of 
the complex I in inner mitochondrial membrane prepara- 
tions. However, in intact mitochondria harbouring the 
ND4/I  1778 mutation, the rates of oxidation of NADH-de- 
pendent substrates, but not succinate, were significantly 
decreased. Similarly, Larsson et al. [30] have reported 
unaffected electron transfer activity of Complex I itself in 
isolated mitochondria from muscles of LHON patients 
with the ND4/11778 mutation, but lowered activities of 
oxidation of NADH-linked substrates. In the study by 
Larsson et al. [30], there was no correlation between the 
degree of complex I deficiency in muscle and the occur- 
rence of optic atrophy. Furthermore, the functional defi- 
ciency was detected in patients with optic atrophy as well 
as in healthy individuals with the mutation. 
A reduction in rotenone-sensitive and ubiquinone-de- 
pendent electron transfer activity was detected in the inner 
mitochondrial membrane preparations from the lym- 
phoblastoid cell lines with the ND1/3460 mutation 
whereas the proximal NADH dehydrogenase activity of 
the complex I was unaffected [29]. This finding is in 
accordance with the suggestion that the NDI subunit inter- 
acts with rotenone and ubiquinone. 
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